Author: Fiona Craig

Watkin Jones plc (LSE:WJG) reported steady profitability for the half year to 31 March 2026, despite a decline in revenue linked to lower transactional activity. The company said operating profit is expected to be broadly in line with the previous year, supported by solid execution across its in-build developments, which delivered margins in line with guidance.

During the period, Watkin Jones secured two new projects, including a purpose-built student accommodation scheme in Bristol and a hotel development in Wimbledon. Its broader development pipeline remained stable, underpinned by a 20% increase in opportunities within its Development Partnerships segment. The group also maintained a strong cash position while continuing to manage cost pressures and adjust its pipeline in response to uncertainty סביב UK interest rates and market liquidity.

Management highlighted disciplined cash management, with gross cash of حوالي £67 million and net cash of roughly £61 million at the end of the period. Although slightly lower than the previous financial year, this level of liquidity remains supportive of ongoing developments. Looking ahead, the company aims to drive stronger performance in the second half by progressing scheme sales, diversifying income streams, and taking proactive steps to control construction cost inflation amid shifting economic and geopolitical conditions.

However, the outlook remains challenging. Watkin Jones continues to face pressure from declining revenues, reduced profitability, and tighter liquidity conditions. Technical indicators also suggest a negative trend in the share price, adding further caution to the investment case.

More about Watkin Jones

Watkin Jones plc is a leading UK developer and manager of residential-for-rent properties, with a strong focus on purpose-built student accommodation and the wider living sector. The company operates across development, asset management, and partnership models, primarily serving institutional investors and residential investment markets across the UK.

Serica Energy plc (LSE:SQZ) has successfully raised $300 million through a new issue of five-year senior unsecured Nordic bonds, with the offering significantly oversubscribed. The bonds carry an annual coupon of 7.875% and attracted strong interest from investors across the Nordic region, the UK, and international markets. Settlement is expected around 12 May 2026, with plans to list the bonds on the Euronext ABM market in Oslo.

The company intends to use the net proceeds to fully repay its drawn Reserve Based Lending (RBL) facility, while retaining the structure for future flexibility. This move is expected to lift pro forma liquidity to approximately $675 million. Management said the transaction enhances balance sheet strength, broadens funding sources, and positions Serica to pursue growth opportunities, including acquisitions and development projects across its North Sea portfolio.

Serica’s outlook reflects a mixed financial picture. Recent performance has been weaker, with a decline in 2025 revenue, a reported net loss, and negative free cash flow. However, these factors are partly offset by strong share price momentum and a supportive earnings outlook, including reaffirmed 2026 guidance, an improving net debt position, and a maintained dividend. Valuation is underpinned by an attractive yield, though the negative price-to-earnings ratio highlights ongoing profitability challenges.

More about Serica Energy

Serica Energy plc is an independent UK oil and gas company focused on the UK Continental Shelf, where it accounts for roughly 10% of domestic gas production. Its key producing assets include the Bruce, Keith, and Rhum fields in the Northern North Sea, as well as interests in fields linked to the Triton FPSO in the Central North Sea. The company also holds a 40% operated stake in the Greater Laggan Area and the Shetland Gas Plant.

Serica is pursuing further growth through acquisitions, including planned stakes in the Catcher and Golden Eagle fields from ONE-Dyas and additional assets from Spirit Energy expected in 2026. Currently listed on AIM under ticker SQZ, the company intends to transition to the London Stock Exchange Main Market as part of its longer-term strategy to expand scale and enhance shareholder value.

Melrose Industries plc (LSE:MRO) reported an 11% increase in first-quarter revenue, supported by robust performance across its key divisions. The Engines business led the way with 20% growth, while Airframes posted a 4% rise, driving adjusted operating profit for both segments and the overall group well above the prior year.

The Engines division benefited from strong deliveries of newer original equipment as well as broad-based aftermarket expansion, particularly in repair activity and military programmes. In Airframes, defence-related demand grew at a double-digit pace, complemented by modest gains in civil aviation. However, lower narrowbody volumes reflected softer conditions across parts of the commercial aerospace market.

Melrose said net debt and free cash flow remained in line with expectations. While the company has limited direct exposure to the Middle East, it highlighted some indirect risks, including rising freight costs and uncertainty around civil aviation activity due to the ongoing conflict. Despite these factors, management reaffirmed its full-year 2026 guidance, projecting revenue between £3.75 billion and £3.95 billion, adjusted operating profit of £700 million to £750 million, and free cash flow in the range of £150 million to £200 million. The outlook reflects confidence in stronger second-half performance and continued growth momentum into 2026 and beyond.

Overall, the company’s prospects are supported by improving operational fundamentals and clear, growth-oriented guidance, including expectations for margin expansion and higher cash generation. However, some challenges remain, particularly around uneven cash conversion and elevated leverage. Technical indicators also weigh on sentiment, with the stock trading below key moving averages, while valuation appears broadly balanced, offering only limited support from dividend yield.

More about Melrose

Melrose Industries plc is a global aerospace and defence company specialising in aircraft engines and airframe systems. It supplies both original equipment and aftermarket services, leveraging proprietary technologies and established positions on major commercial and military aircraft platforms. The group focuses on markets with strong long-term growth potential and resilient demand characteristics.

Jubilee Metals Group (LSE:JLP) has received approval from the High Court of Justice to proceed with a reduction of its share premium account, marking an important legal step in its broader capital restructuring efforts. The change will become effective once the court order and revised statement of capital are formally registered with the Registrar of Companies, enabling the company to gain greater flexibility over future capital allocation and potential shareholder distributions.

This court-approved move aligns with Jubilee’s wider strategy to strengthen its financial structure as it works toward developing an integrated copper operation in Zambia. By optimising its balance sheet, the company aims to improve its ability to fund expansion projects and support shareholder-focused initiatives, reinforcing its platform for long-term growth in copper production.

Despite this strategic progress, the company’s near-term outlook remains weighed down by a sharp decline in recent financial performance, including significant drops in revenue and profitability alongside negative free cash flow. Some support comes from management actions to reduce risk, including asset disposals and operational improvements in Zambia. However, uncertainty persists due to deferred guidance and ongoing operational and financing challenges. Market signals remain mixed to weak, with technical indicators pointing to negative momentum and valuation constrained by continued losses.

More about Jubilee Metals Group

Jubilee Metals Group is a metals processing company listed on AIM in London and on the AltX of the Johannesburg Stock Exchange. It is focused on building a fully integrated copper business in Zambia, targeting annual production of around 25,000 tonnes. The group combines exploration, mining, processing, and refining through assets such as the Roan concentrator, Sable refinery, regional mining operations, and its Large Waste Rock Project, while emphasising innovative technologies and circular resource practices.

PureTech Health plc (LSE:PRTC) is shifting its market focus to the London Stock Exchange, noting that most of its trading liquidity, investor participation, and governance are already based in the U.K. The move reflects an effort to simplify operations and support a more capital-efficient strategy for advancing its therapeutic pipeline.

The company has informed Nasdaq of its plan to voluntarily delist its American Depositary Shares (ADSs), each representing 10 ordinary shares. After the delisting, PureTech intends to deregister from U.S. reporting requirements to reduce compliance and administrative costs. Its ADSs are expected to continue trading in the U.S. on the over-the-counter market through a sponsored Level 1 ADR programme. Management believes this approach will lower overhead, preserve capital, and allow greater focus on research and development as well as long-term value creation.

Looking ahead, PureTech’s outlook reflects a mix of strengths and risks. The company benefits from strong liquidity and encouraging progress across its clinical programmes. Strategic initiatives and positive trial results support a cautiously optimistic view. However, challenges remain around profitability, operational execution, and future funding needs, alongside weaker technical indicators.

More about PureTech Health

PureTech Health plc operates a hub-and-spoke model for developing biotherapeutics, combining internal innovation with externally funded development entities. The company focuses on therapies based on validated biology and significant unmet medical needs. This strategy has produced a broad pipeline of drug candidates, including several therapies approved by the U.S. Food and Drug Administration, while using capital-efficient structures to accelerate development and enhance shareholder value.

Trifast plc (LSE:TRI) said it remains on track to deliver underlying EBIT of about £16 million for the year ending 31 March 2026, broadly in line with market expectations. This comes despite a roughly 7% drop in revenue to £207 million, reflecting the company’s decision to exit lower-margin business lines and continued softness in automotive demand.

Margins strengthened during the period, with gross margins rising to around 30% and group EBIT margins reaching 7.8%. These improvements were driven by internal efficiency measures, tighter inventory management, and ongoing cost control initiatives. The company also maintained a conservative balance sheet, keeping leverage below 1x.

Under its “Recover, Rebuild, Resilience” strategy, Trifast announced plans to shut down its manufacturing operations in Malaysia. The site will transition into a sales and distribution hub, alongside the potential establishment of a shared services centre. Resources are being redirected toward higher-growth regions such as China and India. Management noted that the Malaysia exit, combined with geopolitical disruptions in the Middle East, is expected to reduce FY27 revenue by around £8 million. However, the company pointed to a strong commercial pipeline and reiterated its medium-term goal of achieving EBIT margins above 10%.

Overall, Trifast’s outlook highlights a stable financial foundation supported by operational improvements. That said, challenges persist in driving consistent revenue growth and strengthening cash flow. Positive strategic actions and management confidence provide some support, though technical indicators and valuation metrics suggest a more cautious stance may be warranted.

More about Trifast

Trifast plc is a global specialist in the design, engineering, manufacturing, and distribution of high-performance fastening solutions. The company serves a diverse set of industrial markets, with significant exposure to the automotive sector, where reliability, supply chain efficiency, and customised fastening systems are critical.

Elementis plc (LSE:ELM) delivered a steady start to the year, reporting around 2% organic revenue growth in the first quarter alongside notable improvements in adjusted operating profit and margins. Gains were largely driven by internal efficiency initiatives and pricing measures across its business segments.

Within Personal Care, organic growth was modest, as pricing strength and a favorable product mix helped counter weaker demand in the Americas. The coatings division performed more strongly, with solid organic revenue growth supported by higher volumes in Asia, which more than offset softer conditions in American markets.

The Energy segment continued its positive trajectory, benefiting from operational enhancements at the St. Louis facility. Across the group, margins improved significantly due to cost-saving efforts and better volume performance, while cash generation remained consistent with company expectations. Elementis also noted that ongoing tensions in the Middle East have not materially affected operations due to limited direct exposure. The company confirmed that the planned sale of its pharmaceutical manufacturing business to Associated British Foods is advancing as planned, with completion anticipated in the second quarter. Despite broader macroeconomic and geopolitical uncertainties, full-year 2026 guidance remains unchanged.

From an outlook perspective, Elementis is benefiting from stronger financial stability, including a substantially reduced debt position and continued positive free cash flow. Management commentary points to further progress in margins and earnings per share, supported by clearly defined medium-term targets. However, these strengths are balanced by weaker technical signals, with the stock trading below key moving averages and showing negative momentum indicators. Valuation also presents some risk due to ongoing net losses, reflected in a negative price-to-earnings ratio, alongside some recent softness in revenue trends.

More about Elementis

Elementis plc is a global specialty chemicals group listed on the London Stock Exchange, employing approximately 1,000 people across 19 sites worldwide. The company specializes in rheology and formulation technologies, supplying both natural and synthetic rheology modifiers as well as performance additives. Its products serve industries including personal care, coatings, energy, and construction, and are supported by access to one of the world’s largest high-quality hectorite clay resources.